JP
ACAD icon

Jana Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Jana Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-421,140
Closed -$14.5M – 48
2017
Q1 		$14.5M Buy
421,140
+119,897
+40% +$4.23M 0.27% 35
2016
Q4 		$8.69M Buy
301,243
+151,991
+102% +$4.02M 0.15% 38
2016
Q3 		$4.75M Buy
+149,252
New +$5.06M 0.08% 44

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Jana Partners's ACAD Position: Q2 2017 in Review

Jana Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2017, closing a stake of 421,140 shares — an estimated $14.5M sold.

Jana Partners first reported a position in ACAD in Q3 2016 and held it in 3 quarters. The position peaked at $14.5M in Q1 2017. 203 funds tracked by Wall St. Rank hold ACAD as of Q2 2017.

  • Jana Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Jana Partners sold 421,140 Acadia Pharmaceuticals shares in Q2 2017, an estimated $14.5M.
  • Jana Partners first reported a position in Acadia Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Jana Partners's Acadia Pharmaceuticals position peaked at $14.5M in Q1 2017.
  • 203 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2017.

Based on Jana Partners's 13F filing for Q2 2017, filed 14 Aug 2017.